UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Antitumor activity of the ribonucleotide reductase inhibitor Triapine alone or in combination with paclitaxel

Gynecologic oncology, 2015-04, Vol.137, p.79-79

2015

Volltextzugriff (PDF)

Sexual function among older female cancer survivors

Gynecologic oncology, 2014-06, Vol.133, p.7-8

2014

Volltextzugriff (PDF)

MK-2206 sensitizes BRCA2 mutant ovarian adenocarcinoma to cisplatin and poly ADP (adenosine diphosphate)-ribose polymerase (PARP) inhibitor therapy

Gynecologic oncology, 2014-06, Vol.133, p.86-87

2014

Volltextzugriff (PDF)

Carboplatin hypersensitivity correlates with mutations in the DNA repair enzyme BRCA

Gynecologic oncology, 2017-06, Vol.145, p.113-113

2017

Volltextzugriff (PDF)

A single institution’s experience with a fast, effective carboplatin desensitization protocol and identification of risk factors for high-grade hypersensitivity reactions

Gynecologic oncology, 2017-06, Vol.145, p.123-123

2017

Volltextzugriff (PDF)

Neratinib shows efficacy in the treatment of HER2/neu amplified epithelial ovarian carcinoma in vitro and in vivo

Gynecologic oncology, 2017-06, Vol.145, p.112-112

2017

Volltextzugriff (PDF)

Cervical adenocarcinoma in situ: An institutional retrospective review of surgical management and outcome

Gynecologic oncology, 2015-04, Vol.137, p.76-76

2015

Volltextzugriff (PDF)

Weekly ixabepilone with or without concurrent bevacizumab in the treatment of platinum/taxane-resistant endometrial and ovarian cancers: An institutional experience

Gynecologic oncology, 2014-06, Vol.133, p.69-69

2014

Volltextzugriff (PDF)

Solitomab, an EpCAM/CD3 bispecific antibody (BiTE®), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo

Gynecologic oncology, 2014-06, Vol.133, p.98-98

2014

Volltextzugriff (PDF)

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo

Gynecologic oncology, 2015-04, Vol.137, p.61-61

2015

Volltextzugriff (PDF)

Choice of adjuvant chemotherapy following neoadjuvant carboplatin/paclitaxel and interval debulking

Gynecologic oncology, 2015-04, Vol.137, p.106-107

2015

Volltextzugriff (PDF)

Mutations in the PIK3 pathway as a major determinant of trastuzumab resistance in uterine serous carcinoma

Gynecologic oncology, 2015-04, Vol.137, p.161-162

2015

Volltextzugriff (PDF)

Up-regulation of STAT3 signaling promotes invasion and metastasis of BRCA2-mutated epithelial ovarian cancer

Gynecologic oncology, 2019-06, Vol.154, p.265-265

2019

Volltextzugriff (PDF)

Up-regulation of STAT3 signaling promotes invasion and metastasis of -mutated epithelial ovarian cancer

Gynecologic oncology, 2019-06, Vol.154, p.265

2019

Volltextzugriff (PDF)

Transforming growth factor downregulates homologous recombination repair genes and increases PARP inhibitor sensitivity in BRCA2 wild-type epithelial ovarian cancer cells

Gynecologic oncology, 2018-06, Vol.149, p.69-69

2018

Volltextzugriff (PDF)

Impact of choice of chemotherapy on survival of patients with carcinosarcoma of the ovary: A retrospective review across two academic institutions

Gynecologic oncology, 2018-06, Vol.149, p.192-193

2018

Volltextzugriff (PDF)

Triapine-olaparib combination therapy deters peritoneal progression of PARP inhibitor-resistant epithelial ovarian cancer

Gynecologic oncology, 2018-06, Vol.149, p.74-74

2018

Volltextzugriff (PDF)

The role of AKT and NHEJ pathways in the sensitivity of BRCA2-mutated epithelial ovarian cancer to PARP inhibitors

Gynecologic oncology, 2020-10, Vol.159, p.146-146

2020

Volltextzugriff (PDF)

Surgical approach for interval debulking after neoadjuvant chemotherapy for treatment of advanced ovarian cancer: A single-institution retrospective cohort study

Gynecologic oncology, 2020-10, Vol.159, p.131-131

2020

Volltextzugriff (PDF)

Surgical approach for interval debulking after neoadjuvant chemotherapy for treatment of advanced-stage ovarian cancer

Gynecologic oncology, 2019-06, Vol.154, p.152-152

2019

Volltextzugriff (PDF)

The combination of olaparib (Poly ADP-ribose polymerase inhibitor) with neratinib (pan-HER inhibitor) is synergistic in uterine serous carcinoma overexpressing HER2

Gynecologic oncology, 2019-06, Vol.154, p.34-34

2019

Volltextzugriff (PDF)

Chemotherapy choice and impact on survival of patients with carcinosarcoma of the ovary: A retrospective review

Gynecologic oncology, 2020-10, Vol.159, p.124-125

2020

Volltextzugriff (PDF)

Patient experience with medical marijuana in women with gynecologic malignancies: A single-institution survey-based study

Gynecologic oncology, 2020-10, Vol.159, p.318-318

2020

Volltextzugriff (PDF)

The PARP inhibitor niraparib demonstrates preclinical activity against HRD-deficient carcinosarcomas

Gynecologic oncology, 2020-10, Vol.159, p.255-255

2020

Volltextzugriff (PDF)

Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress HER2/Neu (NCT01367002): Updated survival analysis

Gynecologic oncology, 2020-10, Vol.159, p.7-8

2020

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(42)

Publikationsform

Artikel
(46)

Sprache

Englisch
(46)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Antitumor activity of the ribonucleotide reductase inhibitor Triapine alone or in combination with paclitaxel

Sexual function among older female cancer survivors

MK-2206 sensitizes BRCA2 mutant ovarian adenocarcinoma to cisplatin and poly ADP (adenosine diphosphate)-ribose polymerase (PARP) inhibitor therapy

Carboplatin hypersensitivity correlates with mutations in the DNA repair enzyme BRCA

A single institution’s experience with a fast, effective carboplatin desensitization protocol and identification of risk factors for high-grade hypersensitivity reactions

Neratinib shows efficacy in the treatment of HER2/neu amplified epithelial ovarian carcinoma in vitro and in vivo

Cervical adenocarcinoma in situ: An institutional retrospective review of surgical management and outcome

Weekly ixabepilone with or without concurrent bevacizumab in the treatment of platinum/taxane-resistant endometrial and ovarian cancers: An institutional experience

Solitomab, an EpCAM/CD3 bispecific antibody (BiTE®), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo

Choice of adjuvant chemotherapy following neoadjuvant carboplatin/paclitaxel and interval debulking

Mutations in the PIK3 pathway as a major determinant of trastuzumab resistance in uterine serous carcinoma

Up-regulation of STAT3 signaling promotes invasion and metastasis of BRCA2-mutated epithelial ovarian cancer

Up-regulation of STAT3 signaling promotes invasion and metastasis of -mutated epithelial ovarian cancer

Transforming growth factor downregulates homologous recombination repair genes and increases PARP inhibitor sensitivity in BRCA2 wild-type epithelial ovarian cancer cells

Impact of choice of chemotherapy on survival of patients with carcinosarcoma of the ovary: A retrospective review across two academic institutions

Triapine-olaparib combination therapy deters peritoneal progression of PARP inhibitor-resistant epithelial ovarian cancer

The role of AKT and NHEJ pathways in the sensitivity of BRCA2-mutated epithelial ovarian cancer to PARP inhibitors

Surgical approach for interval debulking after neoadjuvant chemotherapy for treatment of advanced ovarian cancer: A single-institution retrospective cohort study

Surgical approach for interval debulking after neoadjuvant chemotherapy for treatment of advanced-stage ovarian cancer

The combination of olaparib (Poly ADP-ribose polymerase inhibitor) with neratinib (pan-HER inhibitor) is synergistic in uterine serous carcinoma overexpressing HER2

Chemotherapy choice and impact on survival of patients with carcinosarcoma of the ovary: A retrospective review

Patient experience with medical marijuana in women with gynecologic malignancies: A single-institution survey-based study

The PARP inhibitor niraparib demonstrates preclinical activity against HRD-deficient carcinosarcomas

Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress HER2/Neu (NCT01367002): Updated survival analysis

Suchergebnisse filtern